Debra Cafaro
Analyst · Bank of America. Your line is now open
Thank you, Ryan. And good morning to all of our shareholders and other participants, and welcome to the Ventas third quarter earnings call. We are delighted to report on our strong financial results brought to you courtesy of the Ventas advantage, our excellent people, platforms and properties. Today. I'll also discuss our close and pending major transactions and provide an overview of economic and market conditions. Because we've been so productive, there is a lot to cover. Following my remarks, Bob Probst will review our segment performance, financial results and full year expectations. After that we will welcome your questions. Leading with results, this quarter we delivered a $1.03 and normalized FFO per share, representing 5% year-over-year comparable growth. We also demonstrated capital markets excellence and positive trend in our credit profile. As a result, we are also pleased to improve our full year normalized FFO per share and same store NOI guidance. Our strong and consistent performance is fueled by our market position at the exciting intersection of healthcare and real estate. Two large and dynamic industries with powerful fundamentals and growth prospect. Recent activities continue to demonstrate that we are executing on our strategy allocating capital wisely and doing what we said, a Ventas hallmark. We have built an exceptional enterprise that continues to deliver reliable growth and income from a high quality, diverse portfolio on a strong balance sheet. Our innovation over the years and especially the spin-off of most of our skilled nursing assets and other development since the third quarter of 2015 have produced a differentiated business mix and put us in a great position for continued success. Let me highlight just a few of the platforms and property that are driving our positive outlook. First, during the quarter we closed on our exciting and accretive $1.5 billion acquisition of institutional quality like science, innovation and medical real estate leads by top universities, academic medical centers and research companies. Our new tenants include Yale, UPenn Medicine, and WashU. Like other areas of our business, our tenants are market leader accounting for fully 10% of all university life science, research and development spending in the US. This investment represents a great entry into the large and growing healthcare related R&D space. It adds an adjacent business line to Ventas that further diversifies our portfolio and cash flow. At a 6.8% going-cash yield for the 23 Class A operating properties, we are delighted with the Wexford investment. We are also benefiting from an exclusive development pipeline with Wexford. There are two assets already underdevelopment in the portfolio anchored by Duke and Wake Forest and nine development sites for future growth. We are already making progress on a high profile, potential new development project adjacent to UPenn Medical. This demonstrates the attractive growth opportunity that should flow from combining Ventas' capital with best in class developer Wexford. Likewise our investment in Ardent has proven to be a channel for growth. Last year during the third quarter we closed our acquisition of Ardent's hospital real estate and articulated a vision for building formidable, high quality hospital business in this large, dynamic space. We chose Ardent as our beachhead investment because it is a winner and potential consolidator with its good hospitals, significant market presence, attractive payer mix, good quality of care and strong margin. We also design the growth strategy that focus on scaling Ardent's experience management team and strong infrastructure. At that time, we identified some desirable acquisition target and legacy hospital partners for LHP who's at the top of the list because it shared these desirable characteristic. We are now happy to say that Ardent has inked a deal to acquire LHP just like we drew it up on the board. As healthcare premier capital provider, Ventas is fueling Ardent's growth by providing a $700 million secured loan enabling Ardent to acquire LHP. This deal is attractive both financially and strategically for all Ardent partners and shows our continued ability to align with market leaders to support their growth. Financially, the loan will be accretive to Ventas' 2017 earnings with a going in floating interest rate of approximately 8%. Ardent will remain financially strong and expect to achieve significant synergies. We are happy to say that Ardent continues to perform very well on its base business through the third quarter. Strategically, the LHP acquisition expand Ardent's existing business by 50% making it the second largest privately owned hospital company in the US with annual pro forma revenues of $3 billion and major market share in its diversified location. It also provides Ardent with very valuable partnership with top not so profit health system and academic medical center. As a result, the LHP hospital enjoys strong brand recognition, clinical integration, good market and favorable payer relationship. We expect the Ardent LHP deal and our loan to close in the first quarter of 2017 subject to customary regulatory and other condition. Ventas is committed to being a positive influence in our industry to maintaining strong relationships with the nation's leading providers of care and to working collaboratively with them to create value. Recently across our business line we made good progress advancing our customers' interest in areas important to them. Here are a few examples. First, we recently reached mutually beneficial agreement to modify our decade long agreement with Sunrise Senior Living. In short, we provided long term stability in the management contract with Sunrise and Sunrise agreed to reduce the management fees we pay under that agreement on a permanent basis. Other changes to the agreement align the companies towards profitable growth and enable Sunrise and its dedicated on-site employees to focus on providing superior services to seniors and their family. We also entered into a new multiyear pipeline agreement with Sunrise, giving Ventas the right to fund a pool of new Sunrise roundup development. Second, we've also reached agreement with various customers to cooperate with them on modest asset sales or asset buyback. These included the recently completed sale of seven long -term acute care hospitals, or LTACs with Kindred to a new operator. And a pending disposition of 11 non strategic senior living asset with Brookdale. This approach can give the care providers operating flexibility and higher cash flow and also enabled Ventas to recycle capital into attractive development, redevelopment or acquisition opportunities. We are committed to finding way to support our customers' effort to improve their own results and performance in ways that also benefit our portfolio and protect Ventas shareholders. As a result of our portfolio performance and accretive acquisition, we drove good cash flow from operations this quarter too, enabling us to pay our investor a strong and secured dividend of over 4%. We expect our Board to increase our dividend in the fourth quarter of 2016. When we look at the investment market, we continue to see attractive opportunities but we remain highly selective. We focus on deals that would generate reliable cash flow and cash flow growth at an appropriate risk adjusted return. Our capital allocation is also strategic emphasizing sectors with upside and situations like Lillibridge, Atria, Wexford, and Ardent where significant future growth potential exist from consolidation and/or development. Our ability to invest capital across cycle to deliver value to our investors comes from the combination of our advantaged position within fix asset classes or vertical, our strong relationships with market leading customers and platform. And our team hardened experience and skill. The macro environment unbalanced continues to be favorable including GDP growth in the 2% to 3% range and a global thirst for yield that is accelerating foreign investment into US real estate. While the expectation of higher interest rate can initially dampen enthusiasm for REITs and real estate, we are still enjoying the benefit of incredibly low long-term borrowing rate, reasonable job growth, rising household income, low inflation and improving corporate confidence as expressed in surging M&A activity. Hopefully, we will also have certainty about the election soon. All of these conditions should be positive for commercial real estate fundamentals and growth. At Ventas with our need based demographically driven best business, a super track record of consistent reliable growth, external investment opportunities, a terrific credit profile and an advantage business mix, we should continue to thrive. Finally, the third quarter marked the anniversary of our Ardent deal and the successful spin-off of most of our skilled nursing facility. When I reflect on the tremendous improvement in our enterprise since then I really like what I see. Compared to the third quarter of 2015, we still generate over $2 billion in an annualized NOI. Our assets are higher quality, our business is more diverse, and our cash flow is robust and even more reliable. And most of our business is with the nation's leading care providers and research institutions. And we enjoy multiple channels of growth. We are also lucky to have a best in class team that truly enjoys working together for the benefit of shareholders. Now to talk about our positive quarter, I am happy to turn the call over to our CFO, Bob Probst.